表紙:腰椎椎間板ヘルニア(坐骨神経痛)市場:疫学および2030年までの市場予測
市場調査レポート
商品コード
1031005

腰椎椎間板ヘルニア(坐骨神経痛)市場:疫学および2030年までの市場予測

Lumbar Radiculopathy (Sciatica)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030

出版日: | 発行: Mellalta Meets LLP | ページ情報: 英文 181 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.12円
腰椎椎間板ヘルニア(坐骨神経痛)市場:疫学および2030年までの市場予測
出版日: 2021年10月05日
発行: Mellalta Meets LLP
ページ情報: 英文 181 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

腰椎椎間板ヘルニア治療の市場規模は、予測期間を通じて高い成長が見込まれており、2017年から2030年にかけて拡大すると予想されています。この成長の主な原動力となるのは、慢性的なLSR/坐骨神経痛を対象とした新薬の上市です。

坐骨神経痛(医学的には腰部神経根症または腰仙部神経根症(LSR)とも呼ばれます)は、臀部の深部から発生し、大腿部および/または脚部へと伝わる神経痛です。坐骨神経痛は、椎間板ヘルニアや脊髄神経の通る骨の隙間が狭くなること(脊柱管狭窄症)により、腰椎の神経根が圧迫されることで起こります。

坐骨神経痛の約90%は、椎間板ヘルニアが腰椎や仙骨の神経根を圧迫していることが原因で、その後、脊柱管狭窄症や脊柱管の狭窄も坐骨神経痛の痛みの原因となります。坐骨神経痛は妊娠中にも起こることがあり、まれに梨状筋が短縮して坐骨神経を圧迫する梨状筋症候群が8%程度発生することがあります。椎間板ヘルニア、捻挫、帯状疱疹、腰椎の変性などは、数日から数週間の急性坐骨神経痛の原因となりますが、腰椎や椎間板の変性は、外科手術を行わない限り慢性坐骨神経痛を持続させます。

坐骨神経痛は強い痛みと炎症を伴うことが多いのが特徴です。坐骨神経痛はどの年齢でも発生する可能性がありますが、男性は40代から、女性は50代、60代から発生することが多いです。

当レポートでは、腰椎椎間板ヘルニア(坐骨神経痛)市場について調査し、市場の概要とともに、用途別、コンポーネント別、デプロイ別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

  • 主な調査結果

腰椎神経痛(坐骨神経痛)疾患の背景

  • 腰椎椎間板ヘルニア(坐骨神経痛)の定義
  • 症状と原因
  • 病態生理学
  • 診断と診断の推奨事項
  • 鑑別診断

疫学と患者集団

  • 主な調査結果
  • 手法とデータソース
    • 国別の有病率(米国、ドイツ、フランス、イタリア、スペイン、英国、および日本)
    • 腰椎神経痛(坐骨神経痛)の国別の慢性的罹患症例
    • 慢性腰椎神経痛(坐骨神経痛)の国別の治療および難治性の症例
  • 腰椎神経痛(坐骨神経痛)の疫学とモデルパラメータの主な情報源
    • 米国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • 日本

現在の治療法と医療行為

  • 治療と医療行為
  • 薬理学的アプローチ
  • 非薬理学的アプローチ

アンメットニーズ

新たな治療法

  • パイプラインの概要
  • 腰椎椎間板ヘルニア(坐骨神経痛)の治療開発パイプライン
    • 製品分析
      • デキサメタゾンリン酸ナトリウムゲル(Scilex Pharmaceuticals)
        • 製品プロファイル
        • 臨床開発
        • 2030年までの売上と市場機会
      • コンドリアーゼ (Seikagaku Corporation)
        • 製品プロファイル
        • 臨床開発
        • 2030年までの売上と市場機会
      • クロニジン徐放剤(Sollis Therapeutics)
        • 製品プロファイル
        • 臨床開発
        • 2030年までの売上と市場機会
      • ETX-810(Eliem Therapeutics Inc)
        • 製品プロファイル
        • 臨床開発
        • 2030年までの売上と市場機会
      • 徐放性デキサメタゾン(SpineThera)
        • 製品プロファイル
        • 臨床開発
        • 2030年までの売上と市場機会
      • BOL-DP-o-04(Breath of Life International Pharma Ltd)
        • 製品プロファイル
        • 臨床開発
      • KLS-2031(Kolon Life Science)
        • 製品プロファイル
        • 臨床開発

腰椎神経痛(坐骨神経痛)-価格と償還

将来の治療パラダイム

  • 腰椎椎間板ヘルニア(情勢神経痛)競合他社の状況と予想される承認
  • 将来の治療アルゴリズムと競合他社のポジショニング
  • 新たな治療のための重要なデータの要約

現在および新たな治療法の年間費用

市場の見通し

  • 主な調査結果
  • 2030年までの国別市場予測
    • 主要な医薬品市場における腰椎椎間板ヘルニア(坐骨神経痛)を治療するための薬剤の販売、2017~2030年
    • 腰椎椎間板ヘルニア(坐骨神経痛)療法および薬物別患者シェア

国別の市場予測

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

市場の促進要因と抑制要因

目次
Product Code: MM202034

The Lumbar Radiculopathy/LSR (Sciatica) therapeutic market is expected to experience high growth throughout our study period, increasing from 2017 to 2030. The main drivers of this growth will be the launch of new drugs in chronic LSR/sciatica setting, e.g., Dexamethasone sodium phosphate gel / SEMDEXA (Scilex Pharmaceuticals), Condoliase / HERNICORE (Seikagaku Corporation / Ferring Pharmaceuticals), ETX-810 (Eliem Therapeutics Inc), Extended-release Clonidine / Clonidine micropellet (Sollis Therapeutics) and extended-release dexamethasone (SpineThera).

Sciatica (also refferred to as Lumbar Radiculopathy or lumbosacral radiculopathy (LSR) , which is medically defined as lumbar radiculopathy, is nerve pain that originates deep in the buttock and travels down to the thigh and/or leg. Sciatica is commonly caused when a herniated disc or narrowing of the bony opening for spinal nerves (foraminal spinal stenosis) compresses a nerve root in the lumbar spine.

Approximately 90% of cases of sciatica is due to spinal disc herniation pressing on one of the lumbar or sacral nerve roots, followed by spinal stenosis or the narrowing of the spinal canal which is another reason for sciatica pain. Sciatica may also occur during pregnancy and up to 8% cases rarely arises from Piriformis syndrome in which the shortening of piriformis muscle exerts pressure on the sciatic nerve. However, Disc herniation, back sprain, shingles, and degenerative lumbar spine can all cause acute sciatica, lasting from days to weeks, but degeneration of the lumbar spine and discs leads to chronic sciatica that persists unless a surgical intervention is performed.

Sciatica is often characterized by extreme pain and inflammation. Sciatica can occur at any age but often effects men beginning in their 40s and women in their 50s and 60s.

Sciatica - Prevalence (Epidemiology)

The criteria used to diagnose Lumbar Radiculopathy (Sciatica) are those of the diagnostic guidelines provided by various governing bodies. According to these criteria and the KOL perspective, there is no specific tests for sciatica and current diagnosis are mainly done by using tools like neuroimaging, MRI scan, CT myelography, Electromyography (EMG), straight leg raising test and Cerebrospinal fluid analysis. As the diagnosis of lumbosacral radiculopathy (Sciatica) is not specific, there are other conditions that can be differentiated due to the radicular pain. The other conditions in the differential diagnosis of lumbosacral radiculopathy include herniated disc, lumbosacral plexopathy, lumbar spinal stenosis, mononeuropathies, diabetic amyotrophy, cauda equina syndrome, and non-radicular back pain.

"The total prevalent cases of lumbosacral radicular pain (LSR) / sciatica in the G7 countries are projected to increase from 24 million in 2017 to XX million by 2030 with a CAGR of XX% for the study period (2017-2030 ). The United States was estimated to have the highest prevalence of lumbar radiculopathy (sciatica) cases in 2017."

Sciatica - Current Market Size & Forecast Trends

Current market of Sciatica holds treatment options that are supportive like a conservative (nonsurgical) and surgical approaches. Conservative treatment of sciatica further includes physical therapy, behavioral therapies, or pharmacological therapies. Pharmacological therapies includes medications such as non-steroidal anti-inflammatory drugs (NSAIDs), epidural steroid injections (ESIs), opioids etc. that has been used over-the counter and were observed to reduce the swelling and sciatic pain. Patients are treated with a wide variety of medication first and referred for epidural steroid injections as a second step if they fail to respond to pain medication.

"Epidural injections are common. An estimated 10 million to 11 million injections (2.2 million in the Medicare population) are administered annually in the United States. Despite of widespread utilization of ESIs, concerns persist in the market about particulate steroids and potential side effect and safety concerns (e.g., stroke) from current off-label use. As a result, a significant unmet medical need exists within the market for a potent, non-particulate ESI formulation that demonstrates safety and effectiveness in controlled clinical trial evaluations. Therefore, current sciatica market exhibit a critical unmet need to improve the quality of life of the patients since there are no FDA approved therapies to treat the indication and the off-label therapies have several side effects."

The Lumbar Radiculopathy / LSR (Sciatica) market is expected to see high growth during the forecast period. The market in the G7 countries is expected to reach $18 billion in 2030. The lumbar radiculopathy (sciatica) treatment market is divided into acute and chronic lumbar radiculopathy.

"Approximately 70% of acute cases will be recovered with primary treatments and the remaining 30% are expected to fall into the chronic group, referred to here as chronic LSR. "

The market for acute lumbar radiculopathy (Sciatica) is relatively large compared to the market for chronic lumbar radiculopathy (Sciatica) due to the high number of patients and the increase in primary care prescriptions each year.

Report Highlights:

  • Lumbar Radiculopathy (Sciatica)- Current Market Trends
  • Lumbar Radiculopathy (Sciatica)- Current & Forecasted Cases across the G7 Countries
  • Lumbar Radiculopathy (Sciatica)- Market Opportunities And Sales Potential for Agents
  • Lumbar Radiculopathy (Sciatica)- Patient-based Market Forecast to 2030
  • Lumbar Radiculopathy (Sciatica)- Untapped Business Opportunities
  • Lumbar Radiculopathy (Sciatica)- Product Positioning Vis-a-vis Competitors' Products
  • Lumbar Radiculopathy (Sciatica)- KOLs Insight

Table of Contents

Executive Summary

  • Key Findings

Lumbar Radiculopathy (Sciatica) Disease Background

  • Lumbar Radiculopathy (Sciatica) Definition
  • Symptoms & Causes
  • Pathophysiology
  • Diagnosis & Diagnostic Recommendations
  • Differential Diagnosis

Epidemiology and Patient Populations

  • Key Findings
  • Methods and data Sources
    • Country Specific Prevalent Population (US, Germany, France, Italy, Spain, UK, and Japan)
    • Country Specific Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
    • Country Specific Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
  • Key Sources for Lumbar Radiculopathy (Sciatica) Epidemiology and Model Parameters
    • United States
      • United States Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • United States Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • United States Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • Germany
      • Germany Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • Germany Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • Germany Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • France
      • France Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • France Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • France Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • Italy
      • Italy Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • Italy Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • Italy Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • Spain
      • Spain Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • Spain Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • Spain Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • United Kingdom
      • United Kingdom Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • United Kingdom Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • United Kingdom Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
    • Japan
      • Japan Prevalent Population of Lumbar Radiculopathy (Sciatica)
      • Japan Clinical Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
      • Japan Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)

Current Therapies and Medical Practice

  • Treatments & Medical Practices
  • Pharmacological Approaches
  • Non-Pharmacological Approaches

Unmet Needs

Emerging Therapies

  • Pipeline Overview
  • Therapeutic Developments Pipeline for Lumbar Radiculopathy (Sciatica)
    • Product Analysis
      • Dexamethasone sodium phosphate gel (Scilex Pharmaceuticals)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • Condoliase (Seikagaku Corporation)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • Clonidine extended release (Sollis Therapeutics)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • ETX-810 (Eliem Therapeutics Inc)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • Sustained-release dexamethasone (SpineThera)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2030
      • BOL-DP-o-04 (Breath of Life International Pharma Ltd)
        • Product Profile
        • Clinical Development
      • KLS-2031 (Kolon Life Science)
        • Product Profile
        • Clinical Development

Lumbar Radiculopathy (Sciatica)- Pricing & Reimbursement

Future Treatment Paradigm

  • Lumbar Radiculopathy (Sciatica) Competitor Landscape and Approvals Anticipated
  • Future Treatment Algorithms and Competitor Positioning
  • Key Data Summary for Emerging Treatment

Annual Cost of Current & Emerging Therapies

Market Outlook

  • Key Findings
  • Country Specific Market Forecast to 2030
    • Sales of Drugs to Treat Lumbar Radiculopathy (Sciatica) in the Major Pharmaceutical Markets, 2017-2030
    • Patient Share of Lumbar Radiculopathy (Sciatica) Therapies and by Drug

Market Forecast by Country

  • United States
    • United States Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • United States Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • Germany
    • Germany Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • Germany Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • France
    • France Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • France Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • Italy
    • Italy Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • Italy Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • Spain
    • Spain Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • Spain Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • United Kingdom
    • United Kingdom Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • United Kingdom Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)
  • Japan
    • Japan Market for Lumbar Radiculopathy (Sciatica) 2020-2030 (USD Million)
    • Japan Market for Lumbar Radiculopathy (Sciatica) by Therapies 2020-2030 (USD Million)

Market Drivers and Constraints

  • What Factors Are Driving the Market for Lumbar Radiculopathy (Sciatica)?
  • What Factors Are Constraining the Market for Lumbar Radiculopathy (Sciatica)?